International Poverty Forum to Convene Its 2027 Annual Assembly and Think Tank in Saint Lucia

On the 10th anniversary of its founding, in partnership with the government and people of Saint Lucia, IPF brings its global, action-driven approach to poverty eradication to the Caribbean for the first time, March 19–21, 2027

On the 10th anniversary of its founding, in partnership with the government and people of Saint Lucia, IPF brings its global, action-driven approach to poverty eradication to the Caribbean for the first time, March 19–21, 2027

Money Management International Launches Financial Wellbeing AI Lab, Names Inaugural Advisory Council, and Kicks Off Summer Fellowship with NextLadder Ventures, The MIT Bike Shop and Anthropic

New applied AI lab will work to close the gap between Americans who seek financial counseling and those who successfully connect with help; inaugural projects include a summer fellowship with graduate researchers from MIT and Harvard

New applied AI lab will work to close the gap between Americans who seek financial counseling and those who successfully connect with help; inaugural projects include a summer fellowship with graduate researchers from MIT and Harvard

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

HUNTSVILLE, Ala., July 09, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization technology, today announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease.

Anti-Obesity Drugs Market Size to Reach USD 70.31 Billion by 2035 | SNS Insider

The U.S. Anti-Obesity Drugs Market is projected to grow from USD 2.27 Billion in 2025 to USD 19.64 Billion by 2035, while Europe is expected to expand from USD 1.88 Billion to USD 16.94 Billion, supported by increasing GLP-1 therapy adoption, broader reimbursement coverage, and obesity treatment innovation.

The U.S. Anti-Obesity Drugs Market is projected to grow from USD 2.27 Billion in 2025 to USD 19.64 Billion by 2035, while Europe is expected to expand from USD 1.88 Billion to USD 16.94 Billion, supported by increasing GLP-1 therapy adoption, broader reimbursement coverage, and obesity treatment innovation.